Purpose We conducted a phase I clinical trial for patients with advanced cancer and predominant liver disease. Methods Patients were treated with HAI nab-paclitaxel (120-210 mg/m 2 ; day 1); intravenous bevacizumab (10 mg/kg; day 1); and intravenous gemcitabine (600-800 mg/m 2 ; days 1 and 8). A conventional ''3 ? 3'' study design was used.
Introduction
Patients with unresectable hepatic metastases from solid tumors have poor overall survival, and several therapeutic strategies are being investigated to improve outcomes. Hepatic arterial infusion (HAI) of chemotherapy has been used for the treatment of liver metastases since the 1950s [1] . The advantage of administering chemotherapy via the hepatic artery is based on the concept that malignant tumors derive most of their blood supply from the hepatic artery, in contrast to normal hepatocytes that are supplied through the portal venous circulation. Chemotherapy drugs administered via the hepatic artery are thought to be extracted during their initial pass through the hepatic parenchymal tissue; therefore, more drugs are delivered to the liver metastases [2] .
We have previously explored the use of HAI to deliver various chemotherapy regimens for the treatment of patients with advanced metastatic disease in the liver. Our experience with HAI of oxaliplatin, intravenous (IV) 5-fluorouracil (5-FU), leucovorin, and bevacizumab was favorable, particularly in patients with colorectal cancer and predominant liver metastases. This combination was well tolerated and was associated with rates of partial response (PR) and stable disease (SD) C4 months of 11 and 32 %, respectively [3] . We have also reported that HAI of cisplatin combined with IV liposomal doxorubicin was associated with a PR rate of 7 % and an SD C 4 months rate of 45 % [4] . In another phase I study of HAI paclitaxel in patients with advanced cancer and dominant liver involvement, results were disappointing. Treatment was well tolerated, but SD C 4 months was noted only in 13.6 % of patients [5] .
Nab-paclitaxel (Abraxane, Celgene), a novel nanoparticle, albumin-bound form of paclitaxel, is approved by the Food and Drug Administration (FDA) for treating breast cancer. Nab-paclitaxel was developed as a solvent-free paclitaxel to improve the efficacy and reduce the toxicity of solvent-based paclitaxel. It has been shown that nab-paclitaxel is better tolerated than standard paclitaxel [6] . Furthermore, no dose-limiting toxicities were found in a phase I trial of HAI nab-paclitaxel at doses up to 260 mg/m 2 [7] . Bevacizumab is a humanized antibody directed against vascular endothelial growth factor (VEGF). Bevacizumab is an FDA-approved drug for treating various cancers, including colorectal, lung, ovarian, kidney, and breast (outside the USA) cancers and glioblastoma (USA only). An improvement in progression-free survival was noted in a phase III study of paclitaxel in combination with bevacizumab compared with paclitaxel alone for treating metastatic breast cancer (11.8 vs. 5.9 months) [8] .
Gemcitabine, a nucleoside analog, is indicated as a firstline therapy in locally advanced or metastatic disease for the treatment of patients with carcinoma of the pancreas or breast or non-small cell lung cancer. Gemcitabine is also approved in combination with carboplatin for patients with ovarian cancer. In a phase III study, gemcitabine combined with paclitaxel was associated with improved survival compared with paclitaxel alone (18.6 vs. 15.8 months, p = 0.049) in patients with breast cancer [9] .
The FDA approval of nab-paclitaxel for the treatment of breast cancer prompted the initiation of several trials of nab-paclitaxel in combination with other agents, including a phase III study of gemcitabine with or without nab-paclitaxel in pancreatic cancer. On the basis of our favorable experience with HAI regimens in selected patients with advanced solid tumors metastatic to the liver, and because of previously published data showing antitumor activity of IV nab-paclitaxel combined with IV gemcitabine, we conducted a phase I clinical trial of HAI of nab-paclitaxel with IV gemcitabine and IV bevacizumab. The primary objectives were to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD).
Methods

Patients
Patients seen in the Department of Investigational Cancer Therapeutics (Phase I Program) at The University of Texas MD Anderson Cancer Center with histologically confirmed advanced cancer of any type and predominant liver metastases were eligible for the study. Patients had to be C18 years of age and have disease refractory to standard therapy or no standard therapy available to them that increased survival by [3 months. Other criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; [3 weeks after completion of previous therapy; a negative serum pregnancy test for women of childbearing age; and adequate renal (serum creatinine B2 mg/dL), liver (total bilirubin B5 mg/dL and alanine aminotransferase B5 times upper normal reference value), and bone marrow (absolute neutrophil count C1,500 cells/lL; platelets C100,000 cells/lL) function.
Patients were excluded owing to pregnancy; serious non-healing wound, ulcer, or bone fracture; history of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 28 days; uncontrolled systemic vascular hypertension (systolic blood pressure[140 mm Hg, diastolic blood pressure [90 mm Hg); and uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection requiring parenteral antibiotics, psychiatric illness/social situations that would limit compliance with study requirements, and uncompensated liver failure.
Prior to enrollment, all participants signed informed consent forms fully disclosing the investigational nature of the trial. The study protocol was conducted with the approval of and according to the guidelines of the MD Anderson Cancer Center Institutional Review Board (ClinicalTrials.gov identifier: NCT01057264).
Treatment
Patients were admitted for treatment at MD Anderson. A hepatic intra-arterial catheter was placed by an interventional radiologist using the femoral approach [5] . A 5-French angiographic catheter was utilized to select the celiac and/or superior mesenteric artery, and a co-axial 3-French microcatheter was advanced into the desired hepatic artery. Nuclear medicine hepatic artery flow scintigraphy was then performed in all patients following the injection of 5 mCi technetium-99m macroaggregated albumin particles through the HAI catheter, which was used to simulate the distribution of chemotherapeutic agents. Once extrahepatic flow was excluded and appropriate hepatic distribution was confirmed, patients were transferred to the inpatient unit for initiation of HAI therapy. The catheter was removed at the end of the nab-paclitaxel infusion, and hemostasis was achieved by manual compression.
Treatment consisted of HAI nab-paclitaxel in escalating doses ranging from 120 to 210 mg/m 2 (day 1), IV gemcitabine in escalating doses from 600 to 800 mg/m 2 (days 1 and 8), and IV bevacizumab at 10 mg/kg (day 1) ( Table 1 ). The escalating dose levels of nab-paclitaxel and gemcitabine were as follows: level 1 (nab-paclitaxel 120 mg/m (Table 1) . Patients were premedicated with palonosetron at 0.25 mg IV, dexamethasone at 10 mg IV, and ondansetron at 8 mg IV prior to nab-paclitaxel or gemcitabine infusion. Cycles were repeated every 3 weeks until unacceptable toxicity or disease progression. The use of growth factors was acceptable during the clinical study, as clinically indicated.
Patient monitoring
Patients were monitored approximately every 3 weeks by physical examination, hematology and chemistry laboratory studies, vital signs, electrocardiography (within 1 week of first dose and then as clinically indicated), and radiologic imaging scans (baseline, within 30 days of first dose, at the end of cycle 2, and then every 2-3 cycles thereafter). Appropriate tumor markers (serum carcinoembryonic antigen [CEA], alpha fetoprotein [AFP], CA-125, CA27-29, CA19-9 levels) were tested before treatment and every 2-3 cycles.
Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria (NCI CTC) v 4.0 [10] . DLT was assessed during the first treatment cycle and was defined as follows: (1) any grade 3 or 4 non-hematologic toxicity, even if expected and believed to be related to the study medications (except nausea and vomiting, electrolyte imbalances responsive to appropriate regimens, or alopecia); (2) any grade 4 hematologic toxicity lasting C3 weeks despite supportive care or associated with bleeding and/or sepsis; (3) any grade 4 nausea or vomiting lasting [5 days despite maximum anti-nausea regimens; (4) any other grade 3 non-hematologic toxicity, including symptoms/ signs of vascular leak or cytokine release syndrome, but excluding alopecia; or (5) any severe or life-threatening complication or abnormality not covered in the NCI CTCv 4.0 [10] .
Dosing delays/dose modifications
Patients who developed grade 3 hypertension, proteinuria, erythema, thrombocytopenia, nausea, vomiting, or diarrhea were treated with regular medical support, and their therapy continued once the severity was reduced to grade B2. A weekly assessment was performed, and therapy was suspended for a maximum of 3 weeks. If grade 3 DLT occurred, a dose reduction of 25-50 % was allowed after the patient recovered. The choice of drug to be reduced and the degree of the dose reduction were at the discretion of the physician based on the drug toxicity profile and patient status. There was no dose reduction in bevacizumab.
Endpoints and statistical considerations
A standard ''3 ? 3'' study design was followed during the dose escalation phase. The study included an expansion cohort at the MTD level. All treated patients were included in the toxicity analysis.
Tumor response was assessed every 2 cycles (1 cycle = 3 weeks) by an MD Anderson radiologist and verified by a measurement team within the Department of Investigational Cancer Therapeutics using RECIST guidelines (version 1.1) [11] . These criteria defined a PR as a 30 % decrease in the sum of the longest diameters of target lesions, excluding complete disappearance of disease (complete response [CR] ). Progressive disease (PD) was defined as a 20 % increase in the sum of the longest diameters of target lesions. SD was defined as having neither sufficient tumor shrinkage to qualify for PR nor a sufficient increase to qualify for PD. Waterfall plot analysis was used to illustrate antitumor activity, as previously described [3] . Survival was measured from the first day of treatment on the clinical trial until death from any cause or last followup. Progression-free survival (PFS) was measured from the first day of treatment until the patient came off study for either disease progression or death. Patients alive and without progression until the date of last follow-up were censored on that date (including patients who left due to toxicity or who withdrew consent). Patients' characteristics were analyzed using descriptive statistics. Survival functions were estimated using the Kaplan-Meier method.
Results
Demographics
From February 2010 to August 2012, 50 patients with advanced cancer were treated on protocol. Overall, 58 patients were screened. Eight patients were not treated because of insurance/financial issues (n = 3) or ineligibility: fever/hypotension (n = 2) and ECOG performance status 3 (n = 3). The median patient age was 58 years (range 25-79 years). There were 23 men and 27 women. Diagnoses were breast cancer (n = 9), pancreatic cancer (n = 9), cholangiocarcinoma (n = 6), head and neck cancer (n = 4), melanoma (n = 4), neuroendocrine cancer (n = 3), ovarian cancer (n = 3), endometrial cancer (n = 3), colorectal cancer (n = 2), sarcoma (n = 2), gastrointestinal cancer (n = 2), adrenocortical cancer (n = 1), genitourinary cancer (n = 1), and adenocarcinoma of unknown origin (n = 1). Patient pretreatment characteristics are listed in Table 2 . The median number of prior therapies was 3 (range 0-12). Prior therapies are listed in Supplemental Table 1 .
Dose escalation and dose-limiting toxicity
The number of patients treated and cycles completed per dose level and during the expansion phase are summarized in Table 1 . No DLTs were noted during the escalation phase; however, on dose level 4, 3 patients were unable to receive the scheduled gemcitabine on day 8 because of severe thrombocytopenia (2 patients in the second cycle and 1 patient in the first cycle). Therefore, dose level 4 was considered intolerable, and dose level 3 was selected as the MTD (HAI nab-paclitaxel180 mg/m 2 , IV gemcitabine 800 mg/m 2 , and IV bevacizumab 10 mg/kg). To date, 32 patients have been treated in the expansion phase (dose level 3).
Toxicity
In total, 264 cycles were administered. The median number of cycles per patient was 4 (range 1-17). Among the 50 treated patients, 17 (34 %) had no toxic events [grade 1. The most common possibly treatment-related toxicities were thrombocytopenia (n = 17), fatigue (n = 12), neutropenia (n = 10), and constipation (n = 8) (Table 3) . Grade 4 toxicities were thrombocytopenia (n = 4), neutropenia (1), and fatigue (n = 1). Grade 3 toxicities were thrombocytopenia (n = 10), neutropenia (9), fatigue (n = 6), diarrhea (n = 1), constipation (n = 1), vomiting (n = 1), anemia (n = 1), and alopecia (n = 1).
Toxicity profile at the recommended dose
Overall, 38 patients (6 in the dose escalation phase and 32 in the expansion phase) were treated at the maximum dose for a total of 170 cycles (median cycles/patient 2.5; range 1-17). Grade 4 thrombocytopenia was noted in 2 patients. Grade 4 neutropenia was noted in 1 patient. Grade 3 toxicities were thrombocytopenia (n = 8), neutropenia (n = 8), fatigue (n = 6), vomiting (n = 1), diarrhea (n = 1), constipation (n = 1), and alopecia (n = 1). Response Forty-six of 50 patients were evaluable for response. The remaining 4 patients were not evaluable for the following reasons: did not complete first cycle due to toxicity (n = 3) and consent withdrawal before restaging (n = 1). Nine (20 %) patients had a PR, and 9 (20 %) had stable disease for C6 months (Fig. 1a) . Eleven patients (colorectal cancer, n = 1; pancreatic adenocarcinoma, n = 3; cholangiocarcinoma, n = 1; breast carcinoma, n = 2; endometrial cancer n = 1; head and neck cancer, n = 1; neuroendocrine carcinoma, n = 1; adrenocortical carcinoma, n = 1) did not have restaging scans and were considered to have clinically progressive disease. Among 34 patients treated at the MTD who were evaluable for response, 7 (21 %) had a PR and 4 (12 %) had SD for C6 months. Clinical outcomes by tumor type and characteristics of patients who had a PR or SD for C6 months are shown in Tables 4 and 5 , respectively. Interestingly, one of the patients who had a PR was a 66-year-old woman with metastatic endometrial carcinoma with two tumor molecular aberrations, a PIK3CA mutation (M1043V) and a KRAS mutation (G12V). This patient had failed 5 prior therapies, including paclitaxel and carboplatin, intraperitoneal paclitaxel and IV cisplatin, liposomal doxorubicin, gemcitabine, and a phase I study with a PI3 kinase inhibitor. Her PFS duration was 24.1? months, and she continues treatment on protocol.
Overall survival
The median follow-up was 4.3 months (range 0.2-24 months). Twenty-nine of 50 patients have died to date. All deaths were due to progressive disease. The median overall survival duration was 7 months (95 % CI: 4, 22) (Fig. 1b) . The median survival times by tumor type were as follows: breast cancer, 7.0 months; pancreatic adenocarcinoma, 4.3 months; and other tumor types, 10.6 months. Progression-free survival
The median PFS was 4.2 months (95 % CI: 2.7, 8.6) (Fig. 1c) . Eight patients were censored at the time of consent withdrawal (n = 4) or toxicity (n = 4). The median PFS by tumor type was as follows: breast cancer, 3.1 months; pancreatic adenocarcinoma, 2.5 months; and other tumor types, 6.4 months.
Discussion
This is the first study to investigate the combination of HAI nab-paclitaxel, IV gemcitabine, and IV bevacizumab. Dose level 3 (HAI nab-paclitaxel 180 mg/m 2 , IV gemcitabine 800 mg/m 2 , and IV bevacizumab 10 mg/kg) was selected as the MTD. At the MTD, the regimen was well tolerated. Overall, 34 % of patients did not experience toxicity [ grade 1. The most common toxicities were thrombocytopenia (34 %), fatigue (24 %), neutropenia (20 %), and constipation (16 %). Peripheral neuropathy was noted in 1 (2 %) patient (grade 1). This observed rate appears to be significantly lower than the 27 % rate of peripheral neuropathy in our previous phase I study with HAI paclitaxel [5] , and it is consistent with the more favorable neurotoxicity profile of nab-paclitaxel compared to paclitaxel.
Of 46 patients evaluable for response, 9 (20 %) had a PR and 9 (20 %) had SD for C6 months. Taking into consideration that patients were heavily pretreated (median number of prior therapies, 3) and had predominant liver metastases, the antitumor activity in selected patients with breast cancer, pancreatic carcinoma, neuroendocrine cancer, and melanoma is encouraging. The median PFS was 4.2 months, and the median overall survival was 7 months.
As expected, the results of the current study appear to be superior to those noted with single-agent HAI nab-paclitaxel at doses up to 260 mg/m 2 [7] . In the latter study, of 38 treated patients, one with breast cancer and one with cervical cancer had a PR. The response durations were 5 and 15 months, respectively. No other responses were noted [7] . Although the studies were not randomized or controlled and the pretreatment patient characteristics may be different, these results indicate that the addition of IV gemcitabine and IV bevacizumab to HAI nab-paclitaxel contributed to the higher rates of response in the current study.
The results of the current study also compare favorably to those of our prior HAI of paclitaxel study in 26 patients, in which only 13.6 % of patients had SD C 6 months, the median failure-free survival was 1.8 months, and the median overall survival was 8.3 months [5] . However, results of our phase I clinical trial using HAI of cisplatin in combination with IV liposomal doxorubicin in patients with advanced cancer and dominant liver involvement were also promising. In that study, 3 (27 %) patients had a PR and 5 (45 %) had SD for C4 months, and antitumor activity was particularly noted in patients with breast cancer and melanoma [4] .
Various phase II clinical trials using the combination of IV nab-paclitaxel and gemcitabine, with or without bevacizumab, have been conducted in patients with metastatic (20) 18 (39) a One patient withdrew consent prior to restaging imaging studies; three patients did not complete the first cycle due to toxicity and were not evaluable for response b ''Other'' includes sarcoma (n = 2), genitourinary cancer (n = 1), adrenocortical carcinoma (n = 1), other gastrointestinal cancers (n = 2), and unknown adenocarcinoma (n = 1) c Squamous cell carcinoma of the anus d Tumor types: urothelial, adenocarcinoma of the esophagus, and adenocarcinoma of unknown origin breast cancer [12] [13] [14] . Other investigators demonstrated that IV nab-paclitaxel and IV gemcitabine resulted in a CR rate of 8 % and a PR rate of 42 % in 50 patients with metastatic breast cancer [14] . In another phase II study, nabpaclitaxel, gemcitabine, and bevacizumab treatment were associated with a CR rate of 27.6 % and a PR rate of 48.3 % in 30 patients with HER2-negative metastatic breast cancer [12] . Others have shown that nab-paclitaxel was effective in the neoadjuvant setting: the combination of IV nab-paclitaxel with epirubicin and pegfilgrastim in a dose-dense neoadjuvant regimen for the treatment of patients with locally advanced breast cancer had a projected 3-year PFS and OS of 48 and 86 %, respectively [15] . In our current study, patients with breast carcinoma had a PR rate of 22 % and SD C 6 months rate of 33 %. Though breast cancer was only a small subset of our patient population, these findings are encouraging and warrant further study. In a phase I/II trial in patients with advanced pancreatic cancer, it has been reported that IV gemcitabine plus nabpaclitaxel was associated with a response rate of 48 % and resulted in an overall survival duration of 12.2 months [16] . Other studies using IV nab-paclitaxel alone [17] or combined with carboplatin [18] have shown responses in treating patients with metastatic melanoma. Specifically, in a phase II trial of weekly combined nab-paclitaxel and carboplatin, the response rate was 25.6 % [18] . In another phase II trial, single-agent nab-paclitaxel was associated with a response rate of 2.7 % in the previously treated cohort and 21.6 % in the chemotherapy-naïve cohort [17] .
In our study, 3 (33.3 %) of 9 patients with pancreatic adenocarcinoma had a PR (Table 4) . Another notable finding was that 2 (100 %) of 2 patients with melanoma had stable disease for C6 months. An intriguing finding in our study was a PR in a 66-year-old woman with metastatic endometrial carcinoma bearing a PIK3CA mutation (M1043V) and a KRAS mutation (G12V) for whom 5 prior therapies had failed. Her PFS was 24.1? months, and she continues treatment on protocol. To put our results in perspective regarding the results of other studies of IV nabpaclitaxel combination regimens, it should be noted that (a) all of our patients had predominant liver metastases, (b) they had failed multiple prior therapies, and (c) our study used HAI nab-paclitaxel, whereas other studies used IV nab-paclitaxel. Although the current results are encouraging, HAI chemotherapy is costly and may be difficult to administer in community practice. Another limitation of the current study is that SPARC (secreted protein acidic and rich in cysteine) expression was not evaluated, and therefore, no association could be made between this marker and response to HAI abraxanecontaining regimens.
In conclusion, HAI nab-paclitaxel combined with IV gemcitabine and IV bevacizumab was well tolerated and had antitumor activity in selected patients with advanced solid tumors metastatic to the liver. This regimen warrants further investigation in patients with specific tumor types and predominant liver metastases.
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